{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:09:21Z","timestamp":1791461361703,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Telmisartan is a long-acting angiotensin II receptor blocker (ARB) with unique pharmacologic properties, including partial PPAR-\u03b3 activation. Its comparative effectiveness against other ARBs in real-world populations remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, including hypertensive patients aged 55\u201385 years without prior stroke, heart failure, or myocardial infarction. After 1:1 propensity score matching, 41,598 patients were included in each group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Telmisartan use was associated with a significantly lower risk of stroke (HR 0.805, 95% CI 0.751\u20130.863), heart failure (HR 0.75, 95% CI 0.672\u20130.836), and all-cause mortality (HR 0.59, 95% CI 0.542\u20130.642) compared to other ARBs. Subgroup analyses showed consistent benefits across sex, diabetes, chronic kidney disease, and hyperlipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large real-world matched cohort of over 83,000 patients, telmisartan was associated with superior cardiovascular and cerebrovascular outcomes compared to other ARBs, supporting its potential as a preferred antihypertensive agent in high-risk populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1715032","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:52:20Z","timestamp":1769064740000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative effectiveness of telmisartan vs. other angiotensin receptor blockers in reducing hypertension-related cerebrovascular and cardiovascular events: a real-world retrospective study using the TriNetX network"],"prefix":"10.3389","volume":"12","author":[{"given":"Tse-Yu","family":"Chen","sequence":"first","affiliation":[{"name":"Doctoral Program in Translational Medicine, National Chung Hsing University","place":["Taichung, Taiwan"]},{"name":"Department of Neurosurgery, Neurological Institute, Taichung Veterans General Hospital","place":["Taichung, Taiwan"]},{"name":"Rong Hsing Translational Medicine Research Center, National Chung Hsing University","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chun","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, National Chung Hsing University","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Yaw","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Medicine, College of Medicine, Chung Shan Medical University","place":["Taichung, Taiwan"]},{"name":"Division of Allergy, Immunology and Rheumatology, Department of Medicine, Chung Shan Medical University Hospital","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Chih","family":"Hung","sequence":"additional","affiliation":[{"name":"Doctoral Program in Translational Medicine, National Chung Hsing University","place":["Taichung, Taiwan"]},{"name":"Department of Life Sciences, National Chung Hsing University","place":["Taichung, Taiwan"]},{"name":"iEGG and Animal Biotechnology Center, National Chung Hsing University","place":["Taichung, Taiwan"]},{"name":"Advanced Plant and Food Crop Biotechnology Center, National Chung Hsing University","place":["Taichung, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/HJH.0000000000000930","article-title":"Impact of hypertension on mortality and cardiovascular disease burden in patients with cardiovascular risk factors from a general practice setting: the ESCARVAL-risk study","volume":"34","author":"Redon","year":"2016","journal-title":"J Hypertens"},{"key":"B2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/HYPERTENSIONAHA.122.20189","article-title":"Association of lp(a) (lipoprotein[a]) and hypertension in primary prevention of cardiovascular disease: the MESA","volume":"80","author":"Rikhi","year":"2023","journal-title":"Hypertension"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1097\/HJH.0b013e3283281254","article-title":"Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients","volume":"27","author":"Costanzo","year":"2009","journal-title":"J Hypertens"},{"key":"B4","doi-asserted-by":"publisher","first-page":"CD002003","DOI":"10.1002\/14651858.CD002003.pub5","article-title":"Beta-blockers for hypertension","volume":"2012","author":"Wiysonge","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"CD009096","DOI":"10.1002\/14651858.CD009096.pub2","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"2014","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1001\/jama.2022.16797","article-title":"Effect of telmisartan on walking performance in patients with lower extremity peripheral artery disease: the TELEX randomized clinical trial","volume":"328","author":"McDermott","year":"2022","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"B8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/00003495-200666010-00004","article-title":"Telmisartan: a review of its use in the management of hypertension","volume":"66","author":"Battershill","year":"2006","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/S0140-6736(24)01744-6","article-title":"Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial","volume":"404","author":"Rodgers","year":"2024","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.59556\/japi.71.0407","article-title":"Telmisartan plus amlodipine as the preferred initial combination in newly diagnosed Indian patients with hypertension: an expert consensus statements","volume":"71","author":"Dalal","year":"2023","journal-title":"J Assoc Physicians India"},{"key":"B11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1365-2710.2011.01295.x","article-title":"Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes","volume":"37","author":"Suksomboon","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.metabol.2006.04.013","article-title":"Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension","volume":"55","author":"Benndorf","year":"2006","journal-title":"Metab Clin Exp"},{"key":"B15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.2337\/db12-0570","article-title":"Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-delta activation","volume":"62","author":"Li","year":"2013","journal-title":"Diabetes"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1291\/hypres.30.1205","article-title":"Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients","volume":"30","author":"Chujo","year":"2007","journal-title":"Hypertens Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3233\/JAD-230133","article-title":"Telmisartan alleviates Alzheimer\u2019s disease-related neuropathologies and cognitive impairments","volume":"94","author":"Fu","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1447-0594.2011.00746.x","article-title":"Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer\u2019s disease","volume":"12","author":"Kume","year":"2012","journal-title":"Geriatr Gerontol Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1001\/jamaneurol.2024.1714","article-title":"Angiotensin receptor blockers for hypertension and risk of epilepsy","volume":"81","author":"Wen","year":"2024","journal-title":"JAMA Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/ajh\/hpae012","article-title":"Three-year cardiovascular outcomes of telmisartan in patients with hypertension: an electronic health record-based cohort study","volume":"37","author":"Yum","year":"2024","journal-title":"Am J Hypertens"},{"key":"B21","doi-asserted-by":"publisher","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1516126","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1097\/00005344-200312001-00019","article-title":"Clinical implication of morning blood pressure surge in hypertension","volume":"42","author":"Kario","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/IBPC.S130277","article-title":"Morning blood pressure surge: pathophysiology, clinical relevance and therapeutic aspects","volume":"11","author":"Bilo","year":"2018","journal-title":"Integr Blood Press Control"},{"key":"B25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/MBP.0000000000000641","article-title":"Morning blood pressure surge as a predictor of cardiovascular events in patients with hypertension","volume":"28","author":"Renna","year":"2023","journal-title":"Blood Press Monit"},{"key":"B26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4070\/kcj.2009.39.5.180","article-title":"The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension","volume":"39","author":"Jung","year":"2009","journal-title":"Korean Circ J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jcin.2011.09.022","article-title":"Protective effect of telmisartan against endothelial dysfunction after coronary drug-eluting stent implantation in hypertensive patients","volume":"5","author":"Terashima","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1161\/ATVBAHA.112.300985","article-title":"Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival","volume":"33","author":"Siragusa","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3760\/cma.j.issn.0366-6999.20122896","article-title":"Telmisartan promotes proliferation and differentiation of endothelial progenitor cells via activation of akt","volume":"127","author":"Cao","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pupt.2013.11.003","article-title":"Telmisartan attenuates monocrotaline-induced pulmonary artery endothelial dysfunction through a PPAR gamma-dependent PI3K\/akt\/eNOS pathway","volume":"28","author":"Li","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/cbf.3313","article-title":"Telmisartan ameliorates vascular endothelial dysfunction in coronary slow flow phenomenon (CSFP)","volume":"36","author":"Jin","year":"2018","journal-title":"Cell Biochem Funct"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1021\/acs.chemrestox.1c00159","article-title":"Telmisartan mitigates high-glucose-induced injury in renal glomerular endothelial cells (rGECs) and albuminuria in diabetes mice","volume":"34","author":"Zhan","year":"2021","journal-title":"Chem Res Toxicol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/ki.2008.204","article-title":"Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy","volume":"74","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"B35","first-page":"129","article-title":"Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study","volume":"5","author":"Bichu","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1007\/s00592-005-0180-4","article-title":"Preventing renal complications in diabetic patients: the diabetics exposed to telmisartan and enalaprIL (DETAIL) study","volume":"42","author":"Barnett","year":"2005","journal-title":"Acta Diabetol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1715032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:52:22Z","timestamp":1769064742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1715032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":37,"alternative-id":["10.3389\/fcvm.2025.1715032"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1715032","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"article-number":"1715032"}}